A Phase 3 interventional study of placebo and tenecteplase in Dysfunctional Central Venous Access Catheters, sponsored by Genentech, Inc.. Completed. Per ClinicalTrials.gov, last updated 2010-08-10.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This was a Phase III, randomized, double-blind, placebo-controlled study that was conducted at 24 centers in the United States and Canada. 100 adult and pediatric patients with dysfunctional central venous catheters (CVCs) were randomly assigned in a 1:1 ratio to receive an initial dose of either placebo (Arm A) or tenecteplase (Arm B).
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
First submitted after Genentech, Inc. became part of Hoffmann-La Roche.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: placebo · Drug: tenecteplase
Drug: placebo · Drug: tenecteplase
2 mL of placebo instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of placebo). Patients weighing \< 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of tenecteplase). Patients weighing \< 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
Percentage of Patients Who Had Restoration of Central Venous Catheter (CVC) Function Following a Single Administration of Study Drug
Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.
Time frame: 120 minutes after first dose
Percentage of Patients Who Had Restoration of CVC Function Following a Single Administration of Study Drug
Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.
Time frame: 15 minutes after first dose
Percentage of Patients Who Had Restoration of CVC Function Following a Single Administration of Study Drug
Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.
Time frame: 30 minutes after first dose
Percentage of Patients Who Had Restoration of CVC Function Following a Second Administration of Study Drug
Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.
Time frame: 15 minutes after second dose
Percentage of Patients Who Had Restoration of CVC Function Following a Second Administration of Study Drug
Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.
Time frame: 30 minutes after second dose
Percentage of Patients Who Had Restoration of CVC Function Following a Second Administration of Study Drug
Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.
Time frame: 120 minutes after second dose
Percentage of Patients Who Had Restoration of CVC Function Following a Third Administration of Study Drug
Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.
Time frame: 15 minutes after third dose
Percentage of Patients Who Had Restoration of CVC Function Following a Third Administration of Study Drug
Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.
Time frame: 30 minutes after third dose
Percentage of Patients Who Had Restoration of CVC Function Following a Third Administration of Study Drug
Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.
Time frame: 120 minutes after third dose
Percentage of Patients Who Had Restoration of CVC Function Following Administration of One or Two Doses of Tenecteplase
Restoration of CVC function was defined as the successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.
Time frame: Up to 120 minutes post-treatment
Percentage of Patients Who Had Restoration of CVC Function at Any Time During the Study and Who Maintained Catheter Patency the Next Time the Catheter Was Assessed, up to 7 Days Following the Last Dose of Tenecteplase
Restoration of CVC function was defined as the successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.
Time frame: Up to 7 days post-treatment
| Milestone | Placebo + Tenecteplase + Tenecteplase (PTT) | Tenecteplase + Tenecteplase + Placebo (TTP) |
|---|---|---|
| Started | 50 | 50 |
| Completed | 47 | 50 |
| Not completed | 3 | 0 |
Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.
| percentage of participants | Placebo + Tenecteplase + Tenecteplase (PTT) | Tenecteplase + Tenecteplase + Placebo (TTP) |
|---|---|---|
| Percentage of Patients Who Had Restoration of Central Venous Catheter (CVC) Function Following a Single Administration of Study Drug | 23.4 | 60.0 |
Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.
| percentage of participants | Placebo + Tenecteplase + Tenecteplase (PTT) | Tenecteplase + Tenecteplase + Placebo (TTP) |
|---|---|---|
| Percentage of Patients Who Had Restoration of CVC Function Following a Single Administration of Study Drug | 10.6 | 22.0 |
Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.
| Percentage of patients | Placebo + Tenecteplase + Tenecteplase (PTT) | Tenecteplase + Tenecteplase + Placebo (TTP) |
|---|---|---|
| Percentage of Patients Who Had Restoration of CVC Function Following a Single Administration of Study Drug | 19.1 | 44.0 |
Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.
| percentage of participants | Placebo + Tenecteplase + Tenecteplase (PTT) | Tenecteplase + Tenecteplase + Placebo (TTP) |
|---|---|---|
| Percentage of Patients Who Had Restoration of CVC Function Following a Second Administration of Study Drug | 42.6 (28.4 to 56.7) | 70.0 (57.3 to 82.7) |
Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.
| Percentage of patients | Placebo + Tenecteplase + Tenecteplase (PTT) | Tenecteplase + Tenecteplase + Placebo (TTP) |
|---|---|---|
| Percentage of Patients Who Had Restoration of CVC Function Following a Second Administration of Study Drug | 63.8 (50.1 to 77.6) | 82.0 (71.4 to 92.6) |
Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.
| Percentage of patients | Placebo + Tenecteplase + Tenecteplase (PTT) | Tenecteplase + Tenecteplase + Placebo (TTP) |
|---|---|---|
| Percentage of Patients Who Had Restoration of CVC Function Following a Second Administration of Study Drug | 72.3 (59.6 to 85.1) | 88.0 (79.0 to 97.0) |
Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.
| percentage of participants | Placebo + Tenecteplase + Tenecteplase (PTT) | Tenecteplase + Tenecteplase + Placebo (TTP) |
|---|---|---|
| Percentage of Patients Who Had Restoration of CVC Function Following a Third Administration of Study Drug | 83.0 (72.2 to 93.7) | 88.0 (79.0 to 97.0) |
Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.
| Percentage of patients | Placebo + Tenecteplase + Tenecteplase (PTT) | Tenecteplase + Tenecteplase + Placebo (TTP) |
|---|---|---|
| Percentage of Patients Who Had Restoration of CVC Function Following a Third Administration of Study Drug | 85.1 (74.9 to 95.3) | 88.0 (79.0 to 97.0) |
Restoration of CVC function was defined as successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.
| Percentage of patients | Placebo + Tenecteplase + Tenecteplase (PTT) | Tenecteplase + Tenecteplase + Placebo (TTP) |
|---|---|---|
| Percentage of Patients Who Had Restoration of CVC Function Following a Third Administration of Study Drug | 85.1 (74.9 to 95.3) | 88.0 (79.0 to 97.0) |
Restoration of CVC function was defined as the successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.
| percentage of participants | Placebo + Tenecteplase + Tenecteplase (PTT) | Tenecteplase + Tenecteplase + Placebo (TTP) |
|---|---|---|
| Through first tenecteplase instillation | 72.3 (59.6 to 85.1) | 60.0 (46.4 to 73.6) |
| Through second tenecteplase instillation | 85.1 (74.9 to 95.3) | 88.0 (79.0 to 97.0) |
Restoration of CVC function was defined as the successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.
| Percentage of patients | Placebo + Tenecteplase + Tenecteplase (PTT) | Tenecteplase + Tenecteplase + Placebo (TTP) |
|---|---|---|
| Percentage of Patients Who Had Restoration of CVC Function at Any Time During the Study and Who Maintained Catheter Patency the Next Time the Catheter Was Assessed, up to 7 Days Following the Last Dose of Tenecteplase | 81.5 (66.8 to 96.1) | 79.3 (64.6 to 94.1) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo + Tenecteplase + Tenecteplase (PTT) | — | 1/47 (2.1%) | 6/47 (12.8%) |
| Tenecteplase + Tenecteplase + Placebo (TTP) | — | 2/50 (4%) | 14/50 (28%) |
| Event | Placebo + Tenecteplase + Tenecteplase (PTT) | Tenecteplase + Tenecteplase + Placebo (TTP) |
|---|---|---|
| Mental Status ChangesPsychiatric disorders | 1/47 | 0/50 |
| PancytopeniaBlood and lymphatic system disorders | 0/47 | 1/50 |
| Venous ThrombosisVascular disorders | 0/47 | 1/50 |
| Event | Placebo + Tenecteplase + Tenecteplase (PTT) | Tenecteplase + Tenecteplase + Placebo (TTP) |
|---|---|---|
| VomitingGastrointestinal disorders | 0/47 | 2/50 |
| Catheter Site PainGeneral disorders | 0/47 | 2/50 |
| DizzinessNervous system disorders | 0/47 | 2/50 |
| TachycardiaCardiac disorders | 1/47 | 0/50 |
| DiarrhoeaGastrointestinal disorders | 1/47 | 1/50 |
| PyrexiaGeneral disorders | 1/47 | 0/50 |
| Back PainMusculoskeletal and connective tissue disorders | 1/47 | 0/50 |
| Musculoskeletal PainMusculoskeletal and connective tissue disorders | 1/47 | 0/50 |
| Neck PainMusculoskeletal and connective tissue disorders | 1/47 | 0/50 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 1/47 | 0/50 |
| Age, Customized(participants) | Placebo + Tenecteplase + Tenecteplase (PTT) | Tenecteplase + Tenecteplase + Placebo (TTP) | Total |
|---|---|---|---|
| < 2 years | 1 | 3 | 4 |
| ≥ 2 to < 17 years | 14 | 16 | 30 |
| ≥ 17 to < 65 years | 17 | 20 | 37 |
| ≥ 65 years | 15 | 11 | 26 |
| Age Continuous(years) | Placebo + Tenecteplase + Tenecteplase (PTT) | Tenecteplase + Tenecteplase + Placebo (TTP) | Total |
|---|---|---|---|
| Mean | 42.2 ± 28.3 | 37.1 ± 26.6 | 39.6 ± 27.4 |
| Sex: Female, Male(Participants) | Placebo + Tenecteplase + Tenecteplase (PTT) | Tenecteplase + Tenecteplase + Placebo (TTP) | Total |
|---|---|---|---|
| Female | 31 | 26 | 57 |
| Male | 16 | 24 | 40 |
No study locations are listed for this record.
The record gives a start of Nov 2006 and a primary completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2010, 2 years 2 months after primary completion. A results delay was requested in May 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenecteplase